Cancer Genetics Inc (CGIX)

[chmcnfunds]

Analysts Expect Cancer Genetics to Announce ($0.48) EPS (NASDAQ:CGIX)

February 12th, 2015 •

Cancer Genetics logoCancer Genetics (NASDAQ:CGIX) has received a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that cover the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.

Analysts have set a 1-year consensus target price of $14.38 for the company and are forecasting that the company will post ($0.48) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Cancer Genetics an industry rank of 65 out of 265 based on the ratings given to related companies.

Cancer Genetics (NASDAQ:CGIX) opened at 6.99 on Thursday. Cancer Genetics has a 52-week low of $4.83 and a 52-week high of $20.95. The stock’s 50-day moving average is $7.52 and its 200-day moving average is $7.7. The company’s market cap is $68.0 million.

Cancer Genetics (NASDAQ:CGIX) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.10. On average, analysts predict that Cancer Genetics will post $-1.73 earnings per share for the current fiscal year.

Cancer Genetics, Inc (NASDAQ:CGIX) is an early-stage, diagnostic company. The Company focuses on developing and commercializing genomic tests and services to improve the diagnosis, prognosis and response to treatment (theranosis) of cancer.

To get a free copy of the research report on Cancer Genetics (CGIX), click here. For more information about research offerings from Zacks Investment Research, visit Zacks.com
__________________________________________
http://www.americanbankingnews.com/2015/02/12/analysts-expect-cancer-genetics-to-announce-0-48-eps-nasdaqcgix/

CGIX